Fosifloxuridine nafalbenamide

N/A

Report date: 2026/03/17 20:00:15
NME

Base Information

Drug NameFosifloxuridine nafalbenamide
Drug Alias NameFUDR-phosphoramidate5-Fluorouracil ProTide - NuCanafloxuridine prodrug (Rega Institute/Welsh School of Pharmacy)NUC-3373NUC-3073
ClassificationSmall molecules > Nucleosides and nucleotide derivtives
Mechanisms of ActionDNA methylation inhibitorsThymidylate synthase inhibitors
TargetsThymidylate synthase
Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisEndometrial Neoplasms +[16
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesItalyGermany +[6
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCardiff University
China Registration ClassN/A

Develop Information

Active CompaniesNucana Plc
Inactive CompaniesUniversity Of Oxford
Active IndicationsColorectal Neoplasms
Inactive IndicationsSolid tumoursNeoplasm MetastasisEndometrial Neoplasms +[15

Other Information

ATC CodeN/A
Related LinksN/A